Compare Regeneron Pharmaceuticals Inc (REGN) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Rush Street Interactive Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Rush Street Interactive Inc trades at $20.26 (market cap $2.35B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 32.4× Rush Street Interactive Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Rush Street Interactive Inc for 13 Days on average.
| REGN | RSI | |
|---|---|---|
Market Cap | $76.14B | $2.35B |
Volume | 500,239 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $34.52 |
52-Week Low | $557.73 | $15.89 |
Typical Hold Time | 107 Days | 13 Days |
Enterprise Value | $70.85B | $2.01B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
RSI trades at $20.24, down 1.56% with bearish technical signals but strong analyst support. The company shows revenue growth from $1.13B in 2025 to $1.4B projected for 2026, though net income margin compressed from 2.93% to 2.33%. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.1499 expected. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while institutional activity includes BlackRock's $448M investment in August 2026.
The stock presents a compelling valuation gap with consensus price target of $34.88 representing 72% upside, supported by 77% buy ratings from analysts. Key risks include competitive pressures in online gaming and margin compression despite revenue growth. The company's participation in major industry conferences and strong institutional backing provides fundamental support for long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
